This message is sent to you by FDA Newswatch

Cannabinoids As Drugs – Latest Updates 

Tuesday, 29 October 2019 11:30 AM PDT, 02:30 PM EDT

Training Duration = 90 min                  Sponsored by Online Compliance Panel

Click Here to register $229.00

Click Here to register and receive CD recording $329.00

This webinar will discuss the current status of cannabinoids as medical products in the United States. The focus will be on what we can learn from the FDA approval of Epidolex (Cannabidiol) oral solution 100 mg/mL. How to obtain research information will be presented.

The current market for Cannabidiol (CBD) in the United States will also be discussed. This information may be useful in predicting the future of cannabinoids in the United States. The legality of foods containing CBD will be considered.

Objectives of the Presentation:

  • What are Cannabinoids
  • Legal Status of Cannabinoids
  • How was Epidolex approved
  • The current marketing of CBD
  • Research on Cannabinoids
  • Possible future Cannabinoids

Why Should You Attend:

This training will provide valuable information to those who decide which products to pursue and those who develop them or submit their applications. The status of Cannabinoids in the United States is changing rapidly. This webinar will attempt to discuss the latest FDA and market information about them.

Instructor Profile:

Dr. Loren Gelber is currently an independent consultant, based in Charlotte, NC.She previously was employed by Akesis, Bestsweet, RRI, Andrx, Royce, Universal Research, Danbury Pharmacal, Barr and the US FDA. She has been in Regulatory Compliance, Regulatory Affairs, Clinical Research and Quality Control Laboratories.

Dr. Gelber has a Ph.D. in Medicinal Chemistry from Northeastern University, a Masters in Chemistry from Brooklyn Polytechnic and a Bachelors in Biology from Brandeis University.